Loading...
•
Sep 30, 2025
Amicus Therapeutics Q3 2025 Earnings Report
Amicus Therapeutics reported strong third quarter 2025 net product revenue with GAAP profitability and continued double-digit growth across key products.
Key Takeaways
For Q3 2025, Amicus reported total net product revenue of 169061000, up 17% at constant exchange rates year-over-year, and achieved GAAP net income of 17310000 with diluted EPS of 0.06. Galafold and Pombiliti + Opfolda both contributed to growth, with expanded commercial execution driving results.
Total Q3 2025 net product revenue was 169061000.
GAAP net income was 17310000 with diluted EPS of 0.06.
Galafold revenue grew year-over-year to 138347000.
Pombiliti + Opfolda revenue increased to 30714000.
Revenue by Segment
Forward Guidance
Amicus reiterated its 2025 revenue guidance of 15–22% growth and highlighted ongoing expansion opportunities for Galafold and Pombiliti + Opfolda across global markets.
Positive Outlook
- Q3 revenue grew 17% at CER year-over-year.
- GAAP profitability achieved with net income of 17310000.
- Strong growth in Pombiliti + Opfolda revenue.
- Cash and equivalents increased to 263800000.
- Galafold continues to grow in key markets.
Challenges Ahead
- Operating expenses increased year-over-year.
- Non-GAAP operating costs remained elevated.
- EPS remains modest at $0.06.
- Revenue growth, while strong, faced currency headwinds.
- Broad market and reimbursement risks persist.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...